Gilead begins clinical study of inhaled remdesivir for COVID-19 treatment
Gilead Sciences yesterday said it is starting phase one clinical study of inhaled remdesivir for potential outpatient treatment of COVID-19. In a statement, Gilead said the inhaled version could better target respiratory infections and limit systemic exposure to remdesivir and be accessible to non-hospitalized patients. In the placebo-controlled trial, Gilead said it will enroll approximately 60 healthy U.S. adults to evaluate the drug’s safety, tolerability and pharmacokinetics.
Related News Articles
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…